Dr. Paul Peter Tak was included in ‘the Medicine Maker Power List 2023’
https://themedicinemaker.com/awards/power-list/2023
Paul Peter Tak named to PharmaVoice’s 100 List
https://www.pharmavoice.com/digital-edition/july-august-2021/#62
Looking forward to presenting an overview of Candel Therapeutics at the upcoming Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 1:30 PM ET.
https://www.businesswire.com/news/home/20210527005135/en/Candel-Therapeutics-to-Present-at-Upcoming-Jefferies-Virtual-Healthcare-Conference
Prof Paul Peter Tak: Rheumatology, Real Impact and Comfort Zones
Prof Paul Peter Tak is my guest on the podcast this week. He talks to me about growing up in the Netherlands. his medical career and how he ended up specializing in Rheumatology. We chat about his i…
The Story of Flagship Pioneering and The Future of Medicines
James is joined by Dr. Paul-Peter Tak, Venture Partner at Flagship Pioneering and CEO of Kintai Therapeutics. Over a more than 25-year career in the life sciences, Paul-Peter has created and le…
Careers in Discovery
Careers in Discovery is your window into the world of Pharma & Biotech. Featuring interviews each week with leaders in Drug Discovery and R&D, you’ll learn about the careers of these influen…
Listen Notes: Paul-Peter Tak, Academic, business leader and biotech entrepreneur
In this episode, Paul-Peter Tak joins Monica Westley to discuss his innovative ideas within the type 1 diabetes space and how immunology can play a role in helping find a cure for T1D. Paul-Peter is…
Podomatic: Paul-Peter Tak
In biotech, DR. PAUL-PETER TAK, the CEO of Kintai Therapeutics gives us a bigger picture of our gut – it’s not just your microbiome that plays a significant role in the recovery from illness.
Lis…
BIOS APPOINTS BIOTECH LEADER PAUL PETER TAK, MD PHD, AS A STRATEGIC ADVISOR
Cambridge, UK and Montreal, Canada – 5 May, 2021 – BIOS Health, a pioneer in the development of neural interfaces, has appointed world-renowned immunologist and biotechnology business leader, Paul P…
GSK Funds a New Startup with Immunometabolic Focus
Backed by GlaxoSmithKline and Boston’s SV Health Investors, a new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round to develop disea…
